NCT07291141 A Comparative Study of MRI and Ultrasound for Detection of Primary Hepatocellular Carcinoma, Body Composition and Risk Factors for Decompensation in Liver Cirrhosis
| NCT ID | NCT07291141 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mattias Ekstedt |
| Condition | Liver Cirrhoses |
| Study Type | OBSERVATIONAL |
| Enrollment | 600 participants |
| Start Date | 2025-12-18 |
| Primary Completion | 2029-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 600 participants in total. It began in 2025-12-18 with a primary completion date of 2029-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
DETECT-HCC-ESLD is a prospective multicenter study designed to examine early detection and risk stratification of hepatocellular carcinoma (HCC) in individuals with advanced liver disease. Adults with cirrhosis of different etiologies are enrolled and followed longitudinally with structured clinical assessments and imaging at predefined intervals. A key objective is to evaluate ultrasound and abbreviated MRI (AMRI) as surveillance modalities for HCC. The study examines detection performance, feasibility, and factors influencing image quality and interpretability. The protocol also includes the study of body composition, focusing on how variations in adiposity and muscle mass may relate to imaging characteristics, disease progression, and HCC risk. Longitudinal clinical and imaging data are used to explore prediction models aimed at identifying patients with differing levels of HCC risk. The study records outcomes such as incident HCC, liver-related complications, and mortality to support analyses of disease trajectories. The DETECT-HCC-ESLD study provides a structured framework for collecting clinical, imaging, and body composition data over time, enabling detailed evaluation of surveillance strategies and risk patterns in advanced liver disease.
Eligibility Criteria
Inclusion Criteria: * Patients with liver cirrhosis, according to clinical practice. Based on criteria such as elastography, symptoms, biopsy, or radiology. * Age ≥18 years ≤ 84 * Written informed consent from the participant Exclusion Criteria: * Contraindications for MRI (ferrrous material, claustrophobia) * Pregnancy * Diagnosis of primary sclerosing cholangitis (PSC) * Vascular liver disease * Congenital liver fibrosis * Previous diagnosis of hepatic carcinoma (HCC) * Previous liver transplant
Contact & Investigator
Mattias Ekstedt, MD, PhD
PRINCIPAL INVESTIGATOR
Linkoeping University
Frequently Asked Questions
Who can join the NCT07291141 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Liver Cirrhoses. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07291141 currently recruiting?
Yes, NCT07291141 is actively recruiting participants. Contact the research team at mattias.ekstedt@liu.se for enrollment information.
Where is the NCT07291141 trial being conducted?
This trial is being conducted at Linköping, Sweden.
Who is sponsoring the NCT07291141 clinical trial?
NCT07291141 is sponsored by Mattias Ekstedt. The principal investigator is Mattias Ekstedt, MD, PhD at Linkoeping University. The trial plans to enroll 600 participants.